Physician profile
Robert Massingill
NPI 1770587461
$5,269.87
in general payments reported to CMS, 2019-2025
57 companies · $14.23 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,683 · 2020: $178 · 2021: $110 · 2022: $508 · 2023: $1,742 · 2024: $1,034 · 2025: $14.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,726 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,725.57 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $648.09 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Genentech USA, INC. | $528.23 | 2019-2024 | Tecentriq, Polivy, Phesgo |
| Janssen Biotech, INC. | $439.12 | 2019-2024 | Imbruvica, Darzalex, Tecvayli |
| Novartis Pharmaceuticals Corporation | $371.62 | 2019-2024 | |
| Pfizer INC. | $268.55 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $264.44 | 2019-2024 | Alunbrig, Ninlaro |
| Incyte Corporation | $230.25 | 2020-2024 | Monjuvi, Jakafi |
| E.R. Squibb & Sons, L.L.C. | $187.99 | 2019-2024 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $186.17 | 2019-2023 | Imbruvica, Epkinly |
| Daiichi Sankyo INC. | $176.98 | 2020-2024 | Enhertu |
| Celgene Corporation | $162.71 | 2019-2024 | Reblozyl |
| Astrazeneca Pharmaceuticals Lp | $158.59 | 2019-2024 | Imfinzi, Enhertu, Tagrisso |
| Amgen INC. | $140.87 | 2019-2023 | Kyprolis, Blincyto |
| Beigene USA, INC. | $114.96 | 2023-2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $80.85 | 2022-2024 | Libtayo |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Massingill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.